Sanofi S.A. (SNY)

Nasdaq · Paris, France · Founded 1973 · CEO Olivier Charmeil

Valuation summary

$132.16 fair value versus $46.06 in the market, a difference of +186.9%. Rated Strong Buy.

Fair value per share$132.16
Current share price$46.06
Upside / downside+186.9%
Bear case$84.97
Bull case$200.48
Discount rate (WACC)8.4%
Terminal growth2.40%
Market capitalisation$104B
EV / Sales1.9x

About Sanofi S.A.

Traces to 1973, taking its current form through mergers with Synthélabo and Aventis. Olivier Charmeil took over as chief executive in 2026, succeeding Paul Hudson, who had refocused the company on immunology and vaccines and spun off consumer healthcare. Note that the US listing is an ADS: one ordinary Paris-listed share represents two ADSs, so the share count here is stated in ADSs to match the quoted price. Dupixent, an anti-inflammatory treating eczema, asthma and several other conditions, has become one of the largest-selling drugs in the world and drives most of the growth. US-listed as an ADR.

Investment case

  • Dupixent keeps adding approved indications, each expanding the addressable population.
  • Vaccines is a structurally defensive business with high barriers to entry.
  • Trades at a discount to US pharmaceutical peers on comparable pipelines.

Key risks

  • Heavy dependence on a single product — Dupixent is a very large share of growth.
  • European pharmaceutical companies face persistent pricing pressure at home.
  • The pipeline behind Dupixent is less proven than the market would like, and the October 2026 Regeneron deal adds $1 billion upfront and up to $7 billion in milestones for mostly early-stage antibodies.

Recent developments

Revenue by segment

Dupixent & Immunology42%
Vaccines24%
General Medicines26%
Consumer & Other8%

Five-year forecast

RevenueFree cash flow
Year 1$73.2B$12.5B
Year 2$82.3B$14.0B
Year 3$91.7B$15.6B
Year 4$101.2B$17.1B
Year 5$110.7B$18.7B

What the street says

Generally viewed as reasonably valued with real single-product concentration risk. The October 2026 expansion of the Regeneron alliance into long-acting successors to Dupixent is read as an attempt to extend the franchise, while the planned transfer of 20 mature medicines to Cheplapharm continues the narrowing of the portfolio.

Comparable companies: MDT · ABT · SYK · IDXX · TMO · BSX · AZN · ISRG

Open the interactive model, price chart and sensitivity grid →